Appointment of Jefferies and Stifel as brokers

RNS Number : 4784G

Arix Bioscience Plc

30 May 2017

 

Appointment of Jefferies and Stifel as joint corporate brokers

LONDON, 30 May, 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, today announces the appointment of Jefferies International Limited and Stifel Nicolaus Europe Limited to act as its joint corporate brokers with immediate effect.

For more information, please contact:

Arix Bioscience plc

Joe Anderson, CEO

[phone]

Jefferies International Limited

Simon Hardy, Christopher Binks

[phone]

Stifel Nicolaus Europe Limited

Jonathan Senior, Ben Maddison

[phone]

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

[phone]

[e-mail]

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com

 

END

 

 

MSCFKLLLDEFBBBQ